News | ACC | April 11, 2023

Moderate-intensity exercise found not to exacerbate muscle injury by statin users

A newly-published study in the Journal of the American College of Cardiology (JACC), focused on the impact of moderate exercise in patients using statins. 

A newly-published study in the Journal of the American College of Cardiology (JACC) focused on the impact of moderate exercise in patients using statins.

A newly-published study in the Journal of the American College of Cardiology (JACC) found that statin therapy does not exacerbate muscle injury, pain or fatigue in people engaging in moderate-intensity exercise, such as walking.


April 11, 2023 — A newly-published study in the Journal of the American College of Cardiology, JACC, the flagship journal of the American College of Cardiology (ACC), focuses on the impact of moderate exercise in patients using statins. It offers reassuring findings for people who experience muscle pain or fatigue from statins but need to engage in physical activity to keep their cholesterol levels low and their hearts healthy. The study, “Prolonged Moderate-Intensity Exercise Does Not Increase Muscle Injury Markers in Symptomatic or Asymptomatic Statin Users,” found that statin therapy does not exacerbate muscle injury, pain or fatigue in people engaging in moderate-intensity exercise, such as walking. First author on the JACC-published study was Neeltje Allard, MD, researcher at the Department of Integrative Physiology, Radboud University Medical Center in Nijmegen, Netherlands.

Statins have long been the gold standard for lowering LDL or “bad” cholesterol and preventing cardiovascular disease (CVD) events, noted the ACC summary of the published study. It added that while generally well-tolerated, statins can cause muscle pain and weakness in some. Physical activity is a cornerstone of CVD prevention — especially when combined with statins, however, studies have shown vigorous exercise can increase muscle damage in some statin users. This, in turn, can lead to decreased physical activity or cause people to stop taking their medication, which is what led Allard et al to zero in on moderate-intensity activities in the cross-sectional observational study. The researchers’ secondary objective was to also examine the association between leukocyte CoQ10 levels and muscle markers, muscle performance, and reported muscle symptoms.

Study Specifics

Researchers sought to compare the impact of moderate-intensity exercise on muscle injury in symptomatic and asymptomatic statin users, plus nonstatin using controls. Symptomatic vs. asymptomatic was determined by the presence, localization and onset of muscle cramps, pain and/or weakness using the statin myalgia clinical index score. Researchers also examined the association between leukocyte CoQ10 levels on muscle injury and muscle complaints, since statins may lower CoQ10 levels and reduced levels can predispose people to muscle injury.

All study participants walked 30, 40 or 50 km (18.6, 24.8 or 31 miles, respectively) per day at a self-selected pace for four consecutive days. Statin users had all been on the medication for at least three months. The researchers excluded those with diabetes, hypo- or hyperthyroidism, known hereditary skeletal muscle defects, other diseases known to cause muscle symptoms or those using CoQ10 supplementation. There were no differences in body mass index, waist circumference, physical activity levels or vitamin D3 levels (low vitamin D3 levels have been associated with statin-induced myopathy and therefore may be a risk-factor for statin-associated muscle symptoms) among the three groups at baseline.

Researchers concluded “Statin use and the presence of statin-associated muscle symptoms does not exacerbate exercise-induced muscle injury after moderate exercise. Muscle injury markers were not related to leukocyte CoQ10 levels.”

Outcomes and Insights

“Even though muscle pain and fatigue scores were higher in symptomatic statin users at baseline, the increase in muscle symptoms after exercise was similar among the groups,” said Allard. “These results demonstrate that prolonged moderate-intensity exercise is safe for statin users and can be performed by statin users to maintain a physically active lifestyle and to derive its cardiovascular health benefits,” according to Allard.

Researchers did not find a correlation between leukocyte CoQ10 levels and muscle injury markers at baseline or after exercise nor was there a correlation between CoQ10 levels and muscle fatigue resistance or muscle pain scores.

In an accompanying JACC editorial comment, Robert Rosenson, MD, Director of Metabolism and Lipids for the Mount Sinai Health System in New York, said patients experiencing statin associated muscle symptoms will often avoid exercise because of muscle pain and weakness and concerns of making the pain worse; however, exercise is essential for restoring and maintaining fitness in people at increased risk for cardiovascular disease or who have had a cardiovascular event.

“[Based on the study], many patients who develop statin associated muscle symptoms may engage in a moderately intensive walking program without concern for worsened muscle biomarkers or performance,” said Rosenson.

Others joining Allard in conducting the study included: Lando JanssenBart Lagerwaard, Malou A.H. Nuijten, Coen C.W.G. Bongers, Richard J. RodenburgPaul D. ThompsonThijs M.H. EijsvogelsWillem J.J. AssendelftTom J.J. SchirrisSilvie Timmers, and Maria T.E. Hopman.

For more information: www.jacc.org


Related Content

News | ACC

April 11, 2024 — One-year success rates from angioplasty procedures to open clogged arteries in the legs were ...

Home April 11, 2024
Home
News | ACC

April 6, 2024 — The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends in ST ...

Home April 06, 2024
Home
Feature | ACC | Christine Book

April 3, 2024 — In gearing up for its Annual Scientific Session, ACC.24, amidst the 75th anniversary of the organization ...

Home April 03, 2024
Home
News | ACC

March 26, 2024 — Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II ...

Home March 26, 2024
Home
Feature | ACC | By Melinda Taschetta-Millane

The American College of Cardiology (ACC) has announced key educational and programming highlights for its ACC 73rd ...

Home March 25, 2024
Home
News | ACC

March 21, 2024 — Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the goal ...

Home March 21, 2024
Home
News | ACC

March 7, 2024 — The American College of Cardiology (ACC) has announced its line-up of keynote speakers for the ACC 73rd ...

Home March 07, 2024
Home
News | ACC

February 29, 2024 — The American College of Cardiology (ACC) will soon be holding its ACC 73rd Annual Scientific Session ...

Home February 29, 2024
Home
News | ACC

February 14, 2024 — The American College of Cardiology’s newest registry offers data-driven insights on cardiac ...

Home February 14, 2024
Home
News | ACC

February 7, 2024 — The Consumer Technology Association (CTA) and the American College of Cardiology (ACC) are announcing ...

Home February 07, 2024
Home
Subscribe Now